查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714723

再生醫學市場按產品類型、來源、應用領域和最終用戶分類－2025 年至 2030 年全球預測

Regenerative Medicine Market by Product Type, Source, Application Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計再生醫學市場規模到 2024 年將達到 283.5 億美元，到 2025 年將達到 349.9 億美元，複合年成長率為 23.86%，到 ​​2030 年將達到 1,024 億美元。

主要市場統計數據
基準年2024年 283.5億美元
預計2025年 349.9億美元
預測年份 2030 1024億美元
複合年成長率（%） 23.86%

再生醫學處於醫療保健模式轉移的前沿，將生物技術的精確性與創新的治療理念結合。該領域旨在恢復或建立受損組織和器官的正常功能，隨著產業取得重大突破，該領域正在迅速發展。隨著科學的進步和對人體的不斷加深了解，再生醫學有望治療以前無法治癒的疾病，包括神經退化性疾病、心血管疾病和代謝紊亂。

透過利用細胞療法、基因編輯和組織工程等尖端策略的潛力，研究人員正在更接近不僅可以治療症狀而且可以針對疾病根本原因的客製化解決方案。在新技術不斷以前所未有的速度湧現的同時，研究界、臨床醫生和生物技術公司正在進行更廣泛的合作，以彌合基礎科學與臨床應用之間的差距。目前的情況是由跨學科創新的複雜網路定義的，一個領域的突破推動著其他領域的進步。這種動態的相互作用使再生醫學成為一個充滿活力的探索領域，並為未來的個人化治療性介入提供了重要基礎。

該行業的持續發展受到支持性法規環境和投資湧入的推動。隨著臨床試驗逐漸走出早期階段，多種治療方法逐漸接近實用化，綜合涵蓋新興趨勢和經過驗證的科學見解的綜合戰略方針的重要性正變得越來越明顯。進一步的變革正在醞釀中，這將重新定義現代醫療保健的界限。

改變再生醫學市場

近年來，再生醫學領域發生了巨大變化，重新定義了現代醫療保健的可能性。傳統方法正在被新技術和新方法重新發明，挑戰傳統治療方法的限制。基因編輯技術、先進的細胞治療技術和創新的組織工程解決方案的快速發展不僅加快了發展步伐，而且極大地擴展了潛在的臨床應用。

這種轉變得益於對研發的大力投資，推動了曾經純粹是科幻小說的治療方法的商業化。前所未有的公私夥伴關係正在將實驗室見解轉化為現實世界的治療方法。我們看到多學科專業知識的融合，工程師、生物學家和臨床醫生共同努力，確保治療不僅有效，而且可擴展且經濟可行。

這種轉變的核心是數位健康解決方案和再生通訊協定的日益融合，它們共同促進了更個人化的治療方法。利用人工智慧和資料分析的技術平台在簡化臨床試驗、最佳化治療製造和加強病患監測發揮關鍵作用。這種整體綜合的方法將培育一個生態系統，以克服物流、監管和財務挑戰，為創新、永續、以患者為中心的醫療保健新時代鋪平道路。

再生醫學關鍵環節分析

對再生醫學的詳細分析需要了解定義這個動態市場的廣泛細分。從產品類型開始，該市場從多個維度進行考察，包括細胞療法、細胞外療法、細胞療法、基因療法和組織工程。細胞治療本身複雜地分為非幹細胞治療和幹細胞治療，深入挖掘就會發現非幹細胞治療有複雜的子類別，例如免疫細胞和非免疫細胞。深入免疫細胞領域，細分變得更加細緻，包括樹突狀細胞、自然殺手細胞和 T 細胞。

基因療法是這個多面向市場的另一個支柱，人們正在透過基因編輯技術、基因傳遞載體以及基於 RNA 和 DNA 的治療方法進行密切研究。透過考慮非病毒和病毒載體之間的差異，將進一步完善基因轉移載體的研究，強調區分這些方法的安全性和功效結果。組織工程同樣細緻入微，因為它包括生物材料、生長因子和細胞激素以及支架等類別。生物材料領域本身很複雜，可分為天然生物材料和合成生物材料，它們在生物相容性和結構支持方面具有不同的優勢。

市場區隔是根據供應來源和產品類型進行評估的。這考慮了來自同種異體、自體、合成和異種材料的治療方法，每種治療劑都存在監管和製造挑戰。應用領域將進一步豐富分割矩陣，涵蓋心血管、皮膚科、糖尿病、神經學、腫瘤學、眼科學、骨科和肌肉整形外科等臨床頻譜。在這些應用領域中，我們將在每個類別內進行進一步的研究。例如，心血管應用探索血管生成和血管重建、先天性心臟缺陷修復、心臟瓣膜置換和心肌梗塞治療等方面，而皮膚病學則涉及美容手術、燒燙傷治療和慢性創傷治療。神經病學和其他學科保持著類似的細節水平，研究各種疾病的治療方法，從阿茲海默症到脊髓損傷，再到腫瘤學中的腫瘤切除術。最後，按最終用戶細分，市場主要分為學術和研究機構、受託研究機構、醫院和診所以及製藥和生物技術公司，從而全面了解影響該行業的相關人員。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 慢性病的增加和創新治療方法的需求
      • 個人化醫療意識和接受度的不斷提高將推動再生醫學的發展
      • 政府支持再生醫學發展的措施和資金
    • 限制因素
      • 再生醫學的開發成本高且製造複雜
    • 機會
      • 人工智慧主導的再生醫學進步徹底改變了開發和個人化
      • 策略夥伴關係加速再生醫學領域的創新和效率
    • 任務
      • 再生醫學缺乏標準化和複雜的法規結構
  • 市場區隔分析
    • 產品類型：用於再生、替換和修復受損組織和器官的細胞療法需求不斷成長
    • 來源：自體再生醫學對促進癒合和組織修復的重要性
    • 應用：整合腫瘤標靶化方法和腫瘤學中再生醫學的組織修復
    • 最終用戶：生物技術公司擴大採用再生醫學，以利用尖端再生醫學技術
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 再生醫學市場（依產品類型）

  • 細胞療法
    • 非幹細胞療法
      • 免疫細胞
      • 樹突狀細胞
      • 自然殺手（NK）細胞
      • T細胞
      • 非免疫細胞
    • 幹細胞療法
  • 細胞外和無細胞療法
  • 基因治療
    • 基因編輯技術
    • 基因轉移載體
      • 非病毒載體
      • 病毒載體
    • 基於RNA和DNA的治療方法
  • 組織工程
    • 生物材料
      • 天然生醫材料
      • 合成生醫材料
    • 生長因子和細胞激素
    • 鷹架

第7章 再生醫學市場（依來源）

  • 同種異體
  • 自體移植
  • 合成
  • 異質

第8章 再生醫學市場（依應用領域）

  • 心血管系統
    • 血管生成和血管重建
    • 先天性心臟疾病的修復
    • 心臟瓣膜置換術
    • 心肌梗塞的治療
  • 皮膚科
    • 美容手術
    • 燒燙傷治療
    • 慢性創傷治療
  • 糖尿病
    • BETA細胞移植
    • 胰島細胞再生
  • 神經病學
    • 阿茲海默症的治療
    • 多發性硬化症的治療
    • 帕金森氏症的治療
    • 修復脊髓損傷
    • 中風復健
  • 腫瘤學
    • 癌症免疫治療
    • 腫瘤消融
  • 眼科
    • 角膜修復
    • 視網膜再生
  • 整形外科和肌肉骨骼
    • 骨再生
    • 軟骨修復
    • 肌腱修復

第9章 再生醫學市場（依最終使用者）

  • 學術研究所
  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司

第 10 章：美洲再生醫學市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太再生醫學市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 12 章歐洲、中東和非洲的再生醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • 4D Molecular Therapeutics, Inc.
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • CMIC Co., Ltd.
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • Integra LifeSciences Holdings Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Merck KGaA
  • Mesoblast Limited
  • Novartis AG
  • Orchard Therapeutics PLC
  • Organogenesis Holdings Inc.
  • Pluri Biotech Ltd.
  • Poseida Therapeutics, Inc.
  • REPROCELL Inc.
  • SanBio Company Limited
  • Stryker Corporation
  • Sumitomo Pharma Co., Ltd.
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • Tenaya Therapeutics, Inc.
  • Vericel Corporation
  • Voyager Therapeutics Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 28.35 billion in 2024 and is projected to grow to USD 34.99 billion in 2025, with a CAGR of 23.86%, reaching USD 102.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 28.35 billion
Estimated Year [2025] USD 34.99 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.86%

Regenerative medicine stands at the forefront of a paradigm shift in healthcare, melding the precision of biotechnology with innovative therapeutic concepts. This discipline, which strives to restore or establish normal function in damaged tissues and organs, is evolving rapidly as the industry makes significant breakthroughs. Driven by a convergence of scientific advancements and an ever-increasing understanding of the human body, regenerative medicine now holds promise for addressing previously incurable conditions such as neurodegenerative disorders, cardiovascular diseases, and metabolic dysfunctions.

Harnessing the potential of cutting-edge strategies like cell therapy, gene editing, and tissue engineering, researchers are moving closer to tailored solutions that not only treat symptoms but also target the root causes of disease. While new technologies continue to emerge at an unprecedented pace, the research community, clinicians, and biotech companies are collaborating more extensively to bridge fundamental science with clinical application. The current landscape is defined by an intricate network of interdisciplinary innovation, where breakthroughs in one area propel advances in another. This dynamic interplay ensures that regenerative medicine remains a vibrant arena of exploration and provides a vital foundation for the future of personalized therapeutic interventions.

The continuing evolution in this field is bolstered by supportive regulatory environments and an influx of investment. As clinical trials extend beyond early phases and some therapies edge closer to commercial viability, the importance of a comprehensive strategic approach that embraces both emerging trends and proven scientific insights becomes ever more apparent. The stage is set for further transformative changes that will redefine the boundaries of modern healthcare.

Transformative Shifts in the Regenerative Medicine Landscape

Recent years have witnessed dramatic transformative shifts within the regenerative medicine landscape that are redefining what is possible in modern healthcare. Legacy approaches are being reinvented, with new technologies and methodologies challenging the boundaries of traditional treatments. The rapid progression in gene editing technologies, advanced cell therapy techniques, and innovative tissue engineering solutions has not only accelerated the pace of development but has also dramatically expanded the potential applications in clinical practice.

These shifts are underpinned by robust investments in research and development, which have catalyzed the commercialization of therapies that once belonged purely to the realm of science fiction. Unprecedented partnerships across public and private sectors are enabling the translation of laboratory findings into real-world treatments. The landscape is witnessing a consolidation of interdisciplinary expertise where engineers, biologists, and clinicians collaborate to ensure therapies are not only effective but also scalable and economically viable.

At the core of this transformation is the increasing convergence of digital health solutions and regenerative protocols, which together contribute to more personalized treatment approaches. Technology platforms leveraging artificial intelligence and data analytics are playing a crucial role in streamlining clinical trials, optimizing therapy manufacturing, and enhancing patient monitoring. This holistic and integrated approach nurtures an ecosystem primed to overcome logistical, regulatory, and financial challenges, thus paving the way for a new era of innovative, sustainable, and patient-centered care.

Key Segmentation Insights in Regenerative Medicine

An in-depth analysis of regenerative medicine requires understanding the breadth of segmentation that defines this dynamic market. The market is studied across multiple dimensions beginning with product type, where it encompasses cell therapy, extracellular and acellular therapies, gene therapy, and tissue engineering. Within cell therapy itself lies a complex division into non-stem cell-based and stem cell-based therapies, and further exploration reveals the intricate sub-categories within non-stem cell-based therapy such as immune cells and non-immune cells. Delving deeper into the domain of immune cells, the segmentation becomes even more granular by distinguishing among dendritic cells, natural killer cells, and T cells, all of which are critical players in the emerging therapeutic landscape.

Gene therapy forms another pillar of this multi-faceted market and is carefully studied through the lens of gene editing technologies, gene transfer vectors, and RNA & DNA based therapies. The study of gene transfer vectors is further refined by considering the differences between non-viral and viral vectors, highlighting both the safety profiles and efficacy outcomes that differentiate these approaches. Tissue engineering is equally nuanced, as it involves categories such as biomaterials, growth factors & cytokines, and scaffolds. The area of biomaterials is complex in its own right, being segmented into natural and synthetic biomaterials that offer varying advantages in terms of biocompatibility and structural support.

Beyond product types, market segmentation is also evaluated based on source. This involves examining therapies derived from allogeneic, autologous, synthetic, and xenogeneic materials, each presenting unique regulatory and manufacturing challenges. Application areas further enrich the segmentation matrix, as they cover a spectrum of clinical fields including cardiovascular, dermatology, diabetes, neurology, oncology, ophthalmology, and orthopedic & musculoskeletal indications. Within such application areas, each category undergoes additional layers of study. For instance, cardiovascular applications explore dimensions such as angiogenesis and vascular regeneration, congenital heart defect repair, heart valve replacement, and myocardial infarction treatment, while dermatology addresses aesthetic procedures, burn treatment, and chronic wound healing. Neurology and other areas maintain a similar level of detail, scrutinizing therapies intended for conditions ranging from Alzheimer's disease to spinal cord injuries and tumor ablation in oncology. Finally, segmentation by end user dissects the market with a focus on academic and research institutes, contract research organizations, hospitals & clinics, and pharmaceutical and biotechnology companies, thereby offering a comprehensive view of the stakeholders influencing the field.

Based on Product Type, market is studied across Cell Therapy, Extracellular & Acellular Therapies, Gene Therapy, and Tissue Engineering. The Cell Therapy is further studied across Non-Stem Cell-Based Therapy and Stem Cell-Based Therapy. The Non-Stem Cell-Based Therapy is further studied across Immune Cells and Non-immune Cells. The Immune Cells is further studied across Dendritic Cells, Natural Killer (NK) Cells, and T Cells. The Gene Therapy is further studied across Gene Editing Technologies, Gene Transfer Vectors, and RNA & DNA-Based Therapies. The Gene Transfer Vectors is further studied across Non-Viral Vectors and Viral Vectors. The Tissue Engineering is further studied across Biomaterials, Growth Factors & Cytokines, and Scaffolds. The Biomaterials is further studied across Natural Biomaterials and Synthetic Biomaterials.

Based on Source, market is studied across Allogeneic, Autologous, Synthetic, and Xenogeneic.

Based on Application Areas, market is studied across Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Ophthalmology, and Orthopedic & Musculoskeletal. The Cardiovascular is further studied across Angiogenesis & Vascular Regeneration, Congenital Heart Defect Repair, Heart Valve Replacement, and Myocardial Infarction Treatment. The Dermatology is further studied across Aesthetic Procedures, Burn Treatment, and Chronic Wound Healing. The Diabetes is further studied across Beta Cell Transplantation and Islet Cell Regeneration. The Neurology is further studied across Alzheimer's Treatment, Multiple Sclerosis Therapy, Parkinson's Therapy, Spinal Cord Injury Repair, and Stroke Recovery. The Oncology is further studied across Cancer Immunotherapy and Tumor Ablation. The Ophthalmology is further studied across Corneal Repair and Retinal Regeneration. The Orthopedic & Musculoskeletal is further studied across Bone Regeneration, Cartilage Repair, and Tendon Repair.

Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Regional Dynamics and Market Penetration Insights

Regenerative medicine has established a global footprint, with different regions showing distinctive trends in market penetration and growth. In the Americas, research initiatives and a robust funding environment have propelled advances in clinical application, making it one of the leading hubs for innovation in this field. The confluence of strong academic research, supportive healthcare policies, and venture capital investments underscores the region's prominent role in shaping global trends.

Across Europe, the Middle East, and Africa, the market is characterized by a blend of established innovation hubs and emerging research centers. Europe's regulatory frameworks and emphasis on clinical trials have fostered a cautious yet steady adoption of regenerative techniques. Meanwhile, the Middle East and Africa are gradually emerging as promising markets where investments in healthcare infrastructure and technology are beginning to bear fruit, thus contributing to a more balanced and diverse global landscape.

The Asia-Pacific region, driven by strategic government initiatives and expanding biotechnological expertise, is witnessing robust growth in regenerative medicine applications. Accelerated urbanization coupled with a rising middle class promotes demand for advanced therapies, while favorable government policies encourage research and collaborations, setting the stage for exponential market expansion. Across these regions, policy changes, technological advancements, and strategic funding initiatives continue to drive market penetration and provide valuable insights into the evolving dynamics of regenerative medicine on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Major Companies Driving Innovation in Regenerative Medicine

The competitive landscape in regenerative medicine is marked by a diverse group of companies that are accelerating research and development while simultaneously pushing therapeutic boundaries. Key players such as 4D Molecular Therapeutics, Inc. and AbbVie Inc. bring extensive experience in biotherapeutics, while emerging innovators like Abeona Therapeutics Inc. and Adaptimmune Therapeutics PLC are at the forefront of pioneering novel approaches. Companies such as Adverum Biotechnologies, Inc. and AGC Biologics have established themselves by leveraging robust research platforms to address complex clinical challenges.

Other leaders, including Astellas Pharma Inc. and Athersys, Inc., combine clinical expertise with strategic investments to enhance their regenerative medicine portfolios. Recognized global entities such as Bayer AG contribute their longstanding pharmaceutical expertise, while CMIC Co., Ltd. and CRISPR Therapeutics AG integrate cutting-edge gene editing technologies into their development pipelines. Industry giants including F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., and FUJIFILM Holdings Corporation have also carved out significant roles in this domain.

Established players like Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., and Johnson & Johnson continue to push the envelope by investing in transformative medicine. Merging clinical insights with sustainable business strategies, companies such as Merck KGaA, Mesoblast Limited, and Novartis AG are leading the way in bringing innovative therapies to market. Meanwhile, fresh entrants such as Orchard Therapeutics PLC and Organogenesis Holdings Inc. work alongside companies like Pluri Biotech Ltd., Poseida Therapeutics, Inc., REPROCELL Inc., and SanBio Company Limited. This diverse ecosystem is complemented by contributions from Stryker Corporation, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Company Limited, Tenaya Therapeutics, Inc., Vericel Corporation, Voyager Therapeutics Inc., and Zimmer Biomet Holdings, Inc., each playing a pivotal role in propelling the future of regenerative medicine through continuous innovation and strategic market expansion.

The report delves into recent significant developments in the Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., AbbVie Inc., Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Adverum Biotechnologies, Inc., AGC Biologics, Astellas Pharma Inc., Athersys, Inc., Bayer AG, CMIC Co., Ltd., CRISPR Therapeutics AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., Johnson & Johnson, Merck KGaA, Mesoblast Limited, Novartis AG, Orchard Therapeutics PLC, Organogenesis Holdings Inc., Pluri Biotech Ltd., Poseida Therapeutics, Inc., REPROCELL Inc., SanBio Company Limited, Stryker Corporation, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Company Limited, Tenaya Therapeutics, Inc., Vericel Corporation, Voyager Therapeutics Inc., and Zimmer Biomet Holdings, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders navigating the evolving landscape of regenerative medicine need to adopt a proactive strategy that encompasses investment in cutting-edge research, strategic partnerships, and the integration of advanced digital tools. To position themselves effectively, organizations should consider bolstering their research pipelines by investing in next-generation therapeutic platforms and ensuring robust portfolio diversification across various sub-segments. Firms are encouraged to actively pursue collaborations with academic institutions and contract research organizations to access novel technologies and emerging scientific insights, thereby accelerating the translational process from bench to bedside.

Furthermore, a systematic approach to digital transformation is paramount. Embracing data analytics, artificial intelligence, and advanced manufacturing techniques not only enhances operational efficiency but also fosters a more agile response to regulatory and market-driven changes. It is imperative to remain vigilant of evolving regulatory landscapes and to proactively engage with policymakers. Such engagement, coupled with comprehensive clinical data management and patient outcome monitoring, can optimize the pathway towards regulatory approvals and market access.

Lastly, tailoring strategies to address the unique regional and demographic drivers of demand will further solidify market position. For instance, customizing value propositions based on emerging market trends in regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific can offer significant competitive advantages. A detailed risk assessment, open innovation, and an adaptive business model will ensure long-term sustainable growth and secure a leadership position in the competitive realm of regenerative medicine.

Conclusion: Embracing the Future of Regenerative Medicine

The continuing evolution of regenerative medicine is not just a story of scientific brilliance, but a narrative of how collaborative innovation, strategic investments, and well-articulated market segmentation converge to create a transformative healthcare landscape. The current dynamic environment underlines the importance of integrating advanced therapeutic platforms with digital health solutions, thereby promising more personalized and effective treatment modalities.

Our analysis has systematically explored key facets of the market-from detailed segmentation based on product type, source, application areas, and end users, to the geographic nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific. It is clear that each segment provides unique insights into market trends and competitive dynamics, paving the way for novel therapeutic approaches and strategic partnerships. The contributions of major industry players accelerate these advancements, ensuring that breakthroughs in regenerative medicine will continue to shape a future characterized by improved patient outcomes and revolutionary treatment paradigms.

As the industry navigates through both transformative and sometimes turbulent shifts, embracing innovation and forming strategic alliances remain essential. The momentum gained not only reinforces current market trajectories but also sets the stage for further integration of interdisciplinary technologies, ultimately unlocking new possibilities in clinical practice and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases with the need for innovative treatments
      • 5.1.1.2. Growing awareness and acceptance of personalized medicine driving growth in regenerative therapies
      • 5.1.1.3. Government initiatives and funding to support the development of regenerative medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High development cost and manufacturing complexities associated with regenerative medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements AI-driven regenerative medicine revolutionizing its development and personalization
      • 5.1.3.2. Strategic partnerships accelerating innovation and efficiency in regenerative medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization and complex regulatory framework for regenerative medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Rising demand for cell therapy to regenerate, replace, and repair damaged tissues and organs
    • 5.2.2. Source: Significance of autologous regenerative medicine to promote healing and tissue repair
    • 5.2.3. Application Areas: Utilization of regenerative medicine in oncology to integrate tumor-targeting approaches with tissue restoration
    • 5.2.4. End User: Increased adoption of regenerative medicine across biotechnology companies to harness cutting-edge regenerative medicine technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Regenerative Medicine Market, by Product Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Non-Stem Cell-Based Therapy
      • 6.2.1.1. Immune Cells
      • 6.2.1.1.1. Dendritic Cells
      • 6.2.1.1.2. Natural Killer (NK) Cells
      • 6.2.1.1.3. T Cells
      • 6.2.1.2. Non-immune Cells
    • 6.2.2. Stem Cell-Based Therapy
  • 6.3. Extracellular & Acellular Therapies
  • 6.4. Gene Therapy
    • 6.4.1. Gene Editing Technologies
    • 6.4.2. Gene Transfer Vectors
      • 6.4.2.1. Non-Viral Vectors
      • 6.4.2.2. Viral Vectors
    • 6.4.3. RNA & DNA-Based Therapies
  • 6.5. Tissue Engineering
    • 6.5.1. Biomaterials
      • 6.5.1.1. Natural Biomaterials
      • 6.5.1.2. Synthetic Biomaterials
    • 6.5.2. Growth Factors & Cytokines
    • 6.5.3. Scaffolds

7. Regenerative Medicine Market, by Source

  • 7.1. Introduction
  • 7.2. Allogeneic
  • 7.3. Autologous
  • 7.4. Synthetic
  • 7.5. Xenogeneic

8. Regenerative Medicine Market, by Application Areas

  • 8.1. Introduction
  • 8.2. Cardiovascular
    • 8.2.1. Angiogenesis & Vascular Regeneration
    • 8.2.2. Congenital Heart Defect Repair
    • 8.2.3. Heart Valve Replacement
    • 8.2.4. Myocardial Infarction Treatment
  • 8.3. Dermatology
    • 8.3.1. Aesthetic Procedures
    • 8.3.2. Burn Treatment
    • 8.3.3. Chronic Wound Healing
  • 8.4. Diabetes
    • 8.4.1. Beta Cell Transplantation
    • 8.4.2. Islet Cell Regeneration
  • 8.5. Neurology
    • 8.5.1. Alzheimer's Treatment
    • 8.5.2. Multiple Sclerosis Therapy
    • 8.5.3. Parkinson's Therapy
    • 8.5.4. Spinal Cord Injury Repair
    • 8.5.5. Stroke Recovery
  • 8.6. Oncology
    • 8.6.1. Cancer Immunotherapy
    • 8.6.2. Tumor Ablation
  • 8.7. Ophthalmology
    • 8.7.1. Corneal Repair
    • 8.7.2. Retinal Regeneration
  • 8.8. Orthopedic & Musculoskeletal
    • 8.8.1. Bone Regeneration
    • 8.8.2. Cartilage Repair
    • 8.8.3. Tendon Repair

9. Regenerative Medicine Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical & Biotechnology Companies

10. Americas Regenerative Medicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Regenerative Medicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Regenerative Medicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. AskBio earns FDA advanced therapy designation for Parkinson's gene therapy to accelerate clinical trials and drive innovation in regenerative medicine
    • 13.3.2. Tenaya Therapeutics secures an USD 8 million grant from the California Institute for regenerative medicine
    • 13.3.3. UCLA researchers secure USD 21.8 million CIRM grant package to advance innovative stem cell and gene therapies
    • 13.3.4. Bio-Techne expands its R&D Systems portfolio with AI-engineered designer proteins to enhance regenerative medicine innovation
    • 13.3.5. Sysmex Corporation and J-TEC join forces to mechanize and automate regenerative medicine manufacturing processes
    • 13.3.6. Allogene Therapeutics receives FDA RMAT designation for ALLO-316
    • 13.3.7. Bioserve India leverages advanced stem cell tools and reprogramming kits to accelerate clinical trial outcomes and drive innovation in India's regenerative medicine market
    • 13.3.8. Sysmex launches innovative HISCL VEGF and PEDF assay kits to automate secreted protein measurement and reduce quality control costs for regenerative cellular medicine
    • 13.3.9. Cryoport and Minaris strategic partnership integrates advanced cold chain logistics with regenerative medicine
    • 13.3.10. STEMCELL Technologies expands its regenerative medicine platform by acquiring Maryland-based Propagenix
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Gilead Sciences, Inc.
    • 13.4.2. Novartis AG
    • 13.4.3. Bayer AG
    • 13.4.4. AbbVie Inc.

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. AbbVie Inc.
  • 3. Abeona Therapeutics Inc.
  • 4. Adaptimmune Therapeutics PLC
  • 5. Adverum Biotechnologies, Inc.
  • 6. AGC Biologics
  • 7. Astellas Pharma Inc.
  • 8. Athersys, Inc.
  • 9. Bayer AG
  • 10. CMIC Co., Ltd.
  • 11. CRISPR Therapeutics AG
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Fate Therapeutics, Inc.
  • 14. FUJIFILM Holdings Corporation
  • 15. Gilead Sciences, Inc.
  • 16. Integra LifeSciences Holdings Corporation
  • 17. JCR Pharmaceuticals Co., Ltd.
  • 18. Johnson & Johnson
  • 19. Merck KGaA
  • 20. Mesoblast Limited
  • 21. Novartis AG
  • 22. Orchard Therapeutics PLC
  • 23. Organogenesis Holdings Inc.
  • 24. Pluri Biotech Ltd.
  • 25. Poseida Therapeutics, Inc.
  • 26. REPROCELL Inc.
  • 27. SanBio Company Limited
  • 28. Stryker Corporation
  • 29. Sumitomo Pharma Co., Ltd.
  • 30. Sysmex Corporation
  • 31. Takeda Pharmaceutical Company Limited
  • 32. Tenaya Therapeutics, Inc.
  • 33. Vericel Corporation
  • 34. Voyager Therapeutics Inc.
  • 35. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET MULTI-CURRENCY
  • FIGURE 2. REGENERATIVE MEDICINE MARKET MULTI-LANGUAGE
  • FIGURE 3. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 4. REGENERATIVE MEDICINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. REGENERATIVE MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 118. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 136. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 150. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 154. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 159. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 161. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 162. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 163. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 166. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 168. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 172. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 218. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 221. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 222. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 224. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 228. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 233. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 235. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 236. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 237. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 239. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 240. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 242. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 246. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 251. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 253. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 254. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 255. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 256. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 257. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 258. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 260. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 264. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 269. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 271. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 272. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 273. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 274. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 275. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 276. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 278. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 282. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 287. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 289. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 290. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 291. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 292. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 293. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 294. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 296. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 300. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 303. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 305. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 307. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 308. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 309. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 311. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 312. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 314. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 318. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 321. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 323. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 324. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 326. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 328. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 329. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 330. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. PHI